Biomarker Discovery
Accelerate drug discovery & identifying novel therapeutic targets
Why Study
Biomarkers?
Biomarkers are pivotal in modern drug discovery, driving the demand for technologies capable of swiftly identifying highly specific markers. Next-Generation Sequencing (NGS) addresses this need through its unbiased, high-throughput analysis.
This is further enhanced by single-cell technologies like single-cell RNA sequencing (scRNA-seq), single-cell immune profiling (scBCR-seq/TCRseq) which provide unprecedented resolution.
As a CLIA-certified and CAP-accredited lab, Admera Health’s wealth of experience in both discovery and validation of new preclinical biomarkers for research and the analysis of known clinical biomarkers makes for the preferred partner for biomarker discovery.
What You Can Do With Biomarker Discovery
Faster, more targeted drug development
Optimized disease monitoring and management
Enhanced prediction of treatment response & prognosis
Improved disease diagnosis and classification
Revolutionize Research
Admera Health is at the forefront of adopting these cutting-edge single-cell approaches, providing clients with the confidence to explore this new frontier in biomarker discovery with a trusted and experienced partner to drive personalized medicine and accelerate breakthroughs in cancer research.
Our expertise in these cutting-edge methods ensures the rapid and reliable identification of specific biomarkers, leading to:
Improved Disease Diagnosis and Classification
Enhanced Prediction of Treatment Response and Prognosis
Faster and More Targeted Drug Development
Optimized Disease Monitoring and Management
Why Customers Choose Admera Health for Biomarker Discovery Solutions
High Quality Deliverables
Unmatched PhD Support
US-Based Operations
End-to-End Workflows
CLIA/CAP & CLEP Accreditation
Rapid Turnaround
Optimized Workflow
Newly Acquired & Fully Equipped Histology Lab
Admera Health offers a comprehensive biomarker discovery workflow. A. DNA/RNA isolation from samples. B. NGS-based multi-omics profiling (WES, RNA-seq, scRNA-seq, BCR/TCR-seq, scBCR-seq/scTCR-seq, ctDNA-seq) for comprehensive genomic and transcriptomic analysis, including immune repertoire sequencing. Proteomics via partnerships. C. High-throughput sequencing. D. Bioinformatics for biomarker identification and validation.
Deliverables
Immune checkpoint inhibitor biomarker analysis
Including Tumor mutational burden, dMMR, MSI, immune checkpoint expression
Tumor microenvironment profiling and diversity analysis
Cytokine/chemokines profiling
Gut microbiome profiling
Circulating tumor DNA (ctDNA) analysis
Protein expression and phosphorylation analysis
Get the Most out of Your Research
Maximize your project’s potential with advanced data analysis solutions. Our team of expert bioinformaticians curate pipelines tailored to your project’s experimental design
See our sample submission guideline for sample preparation, packing, and shipping instructions.
